Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial
作者: Thomas WiegelDetlef BartkowiakDirk BottkeReinhard ThammAxel HinkeMichael StöckleChristian RübeAxel SemjonowManfred WirthStephan StörkelReinhard GolzRita Engenhart-CabillicRainer HofmannHorst-Jürgen FeldmannTilman KälbleAlessandra SiegmannWolfgang HinkelbeinUrsula SteinerKurt Miller
作者单位: 1Department of Radiation Oncology, University Hospital Ulm, Germany
2WiSP, Research Institute Pharma GmbH, Langenfeld, Germany
3Department of Urology, University Hospital Homburg/Saar, Germany
4Department of Radiation Oncology, University Hospital Homburg/Saar, Germany
5Department of Urology, University Hospital Münster, Germany
6Department of Urology, University Hospital Dresden, Germany
7Department of Pathology, HELIOS Hospital Wuppertal, Germany
8Department of Radiation Oncology, University Hospital Giessen-Marburg, Germany
9Department of Urology, University Hospital Giessen-Marburg, Germany
10Department of Radiation Oncology, General Hospital Fulda, Germany
11Department of Urology, General Hospital Fulda, Germany
12Department of Radiation Oncology, University Hospital Berlin, Germany
13Department of Urology, University Hospital Berlin, Germany
刊名: International Journal of Radiation Oncology, Biology, Physics, 2015, Vol.91 (2), pp.288-294
来源数据库: Elsevier Journal
DOI: 10.1016/j.ijrobp.2014.09.039
原始语种摘要: Objective(#br)The ARO 96-02 trial primarily compared wait-and-see (WS, arm A) with adjuvant radiation therapy (ART, arm B) in prostate cancer patients who achieved an undetectable prostate-specific antigen (PSA) after radical prostatectomy (RP). Here, we report the outcome with up to 12 years of follow-up of patients who retained a post-RP detectable PSA and received salvage radiation therapy (SRT, arm C).(#br)Methods and Materials(#br)For the study, 388 patients with pT3-4pN0 prostate cancer with positive or negative surgical margins were recruited. After RP, 307 men achieved an undetectable PSA (arms A + B). In 78 patients the PSA remained above thresholds (median 0.6, range 0.05-5.6 ng/mL). Of the latter, 74 consented to receive 66 Gy to the prostate bed, and SRT was applied at a...
全文获取路径: Elsevier  (合作)

  • Data 数据